At the time of writing, Prelude Therapeutics Inc [PRLD] stock is trading at $1.30, up 46.40%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PRLD shares have gain 62.50% over the last week, with a monthly amount glided 35.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Prelude Therapeutics Inc [NASDAQ: PRLD] stock has seen the most recent analyst activity on September 19, 2024, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, Barclays downgraded its rating to Underweight on June 20, 2024, and kept the price target unchanged to $3. On March 13, 2024, JMP Securities initiated with a Mkt Outperform rating and assigned a price target of $7 on the stock. H.C. Wainwright downgraded its rating to a Neutral but stick to its price target of $5 on February 20, 2024. Morgan Stanley downgraded its rating to a Underweight and reduced its price target to $4 on December 19, 2023. BofA Securities downgraded its rating to Underperform for this stock on November 21, 2022, and downed its price target to $6. In a note dated September 09, 2022, Morgan Stanley downgraded an Equal-Weight rating on this stock and revised its target price from $19 to $11.
For the past year, the stock price of Prelude Therapeutics Inc fluctuated between $0.80 and $6.80. Currently, Wall Street analysts expect the stock to reach $5 within the next 12 months. Prelude Therapeutics Inc [NASDAQ: PRLD] shares were valued at $1.30 at the most recent close of the market. An investor can expect a potential return of 284.62% based on the average PRLD price forecast.
Analyzing the PRLD fundamentals
Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -22.3%, Pretax Profit Margin comes in at -20.47%, and Net Profit Margin reading is -20.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.67, Equity is -0.67 and Total Capital is -0.82.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0083 points at the first support level, and at 0.7165 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5209, and for the 2nd resistance point, it is at 1.7417.
Ratios To Look Out For
It is important to note that Prelude Therapeutics Inc [NASDAQ:PRLD] has a current ratio of 7.04. In addition, the Quick Ratio stands at 7.04 and the Cash Ratio stands at 0.5. Considering the valuation of this stock, the price to sales ratio is 34.92, the price to book ratio is 0.46.
Transactions by insiders
Recent insider trading involved Lim Bryant David, CLO, Interim CFO, Corp Sec., that happened on Dec 19 ’24 when 25000.0 shares were purchased. CEO, Vaddi Krishna completed a deal on Dec 18 ’24 to buy 100000.0 shares. Meanwhile, CEO Vaddi Krishna bought 6888.0 shares on Dec 19 ’24.
